JP2007528409A - プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置 - Google Patents

プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置 Download PDF

Info

Publication number
JP2007528409A
JP2007528409A JP2007503004A JP2007503004A JP2007528409A JP 2007528409 A JP2007528409 A JP 2007528409A JP 2007503004 A JP2007503004 A JP 2007503004A JP 2007503004 A JP2007503004 A JP 2007503004A JP 2007528409 A JP2007528409 A JP 2007528409A
Authority
JP
Japan
Prior art keywords
aat
functionally active
less
active portion
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007503004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007528409A5 (https=
Inventor
フィリップ エー． ペンバートン，
フィリップ ジェイ． バー，
ヘレン エル． ギブソン，
Original Assignee
アリバ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリバ ファーマシューティカルズ， インコーポレイテッド filed Critical アリバ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2007528409A publication Critical patent/JP2007528409A/ja
Publication of JP2007528409A5 publication Critical patent/JP2007528409A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES OF CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
    • A24D1/00—Cigars; Cigarettes
    • A24D1/002—Cigars; Cigarettes with additives, e.g. for flavouring
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES OF CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
    • A24D3/00—Tobacco smoke filters, e.g. filter tips or filtering inserts; Filters specially adapted for simulated smoking devices; Mouthpieces of cigars or cigarettes
    • A24D3/06—Use of materials for tobacco smoke filters
    • A24D3/14—Use of materials for tobacco smoke filters of organic materials as additive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2007503004A 2004-03-09 2005-03-09 プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置 Pending JP2007528409A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55185604P 2004-03-09 2004-03-09
PCT/US2005/007959 WO2005086915A2 (en) 2004-03-09 2005-03-09 Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor

Publications (2)

Publication Number Publication Date
JP2007528409A true JP2007528409A (ja) 2007-10-11
JP2007528409A5 JP2007528409A5 (https=) 2009-08-06

Family

ID=34976236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007503004A Pending JP2007528409A (ja) 2004-03-09 2005-03-09 プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置

Country Status (6)

Country Link
US (1) US7914771B2 (https=)
EP (1) EP1737499A4 (https=)
JP (1) JP2007528409A (https=)
AU (1) AU2005221151A1 (https=)
CA (1) CA2559062A1 (https=)
WO (1) WO2005086915A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528234A (ja) * 2013-08-05 2016-09-15 フォールマン、ジェラルド 喫煙の悪影響を減らす新規手段

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
EP1737499A4 (en) * 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
EP1981572B1 (en) 2006-02-09 2012-11-21 Kamada Ltd. Pulmonary delivery of alpha-i proteinase inhibitor
WO2008053199A1 (en) * 2006-10-30 2008-05-08 Astrazeneca Ab Combination therapy for the treatment of respiratory diseases
GB0716026D0 (en) * 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
AU2012275295B2 (en) * 2011-06-28 2016-11-10 Inhibrx, Lp WAP domain fusion polypeptides and methods of use thereof
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
KR102231139B1 (ko) * 2011-06-28 2021-03-24 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
KR20140108516A (ko) 2011-12-30 2014-09-11 그리폴스, 에스.에이. 폐 악화의 발현 또는 진행을 지연시키기 위한 알파1-프로테이나제 억제제
WO2014089262A1 (en) * 2012-12-07 2014-06-12 Virginia Commonwealth University Diagnosis and therapy of chronic inflammation-induced disorders
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
WO2018116300A1 (en) * 2016-12-22 2018-06-28 Kamada Ltd. Dry powder formulations of alpha-1 antitrypsin
EP3915574A1 (en) * 2020-05-27 2021-12-01 Grifols Worldwide Operations Limited Method for the treatment of cytokine release syndrome
US12440488B2 (en) 2020-12-01 2025-10-14 Reverspah Llc Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension
US11324694B1 (en) * 2021-10-28 2022-05-10 Cmpd Licensing, Llc Nebulization formulations for delivery to lower respiratory tract
WO2023091081A2 (en) * 2021-11-16 2023-05-25 Agency For Science, Technology And Research Inhalable recombinant protein powder formulation for treating genetic and autoimmune disorders
EP4480493A1 (en) 2023-06-22 2024-12-25 AATEC Medical GmbH A recombinant human alpha-1 antitrypsin glycoprotein for treating non-viral inflammatory diseases of the lung

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1045799A (ja) * 1982-08-13 1998-02-17 Zymogenetics Inc 形質転換酵母を用いて製造した蛋白質
WO2003035610A1 (en) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Sulfonamide derivative having mmp inhibitory activity
JP2003523393A (ja) * 2000-02-25 2003-08-05 アラキス リミテッド 呼吸器疾患治療用メタロプロティナーゼ阻害剤
WO2003091242A1 (en) * 2002-04-26 2003-11-06 Takeda Pharmaceutical Company Limited Novel thiol derivative, process for producing the same and use thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4083372A (en) 1976-05-24 1978-04-11 Robert Boden Cigarette-simulating inhaler
US4393884A (en) 1981-09-25 1983-07-19 Jacobs Allen W Demand inhaler for oral administration of tobacco, tobacco-like, or other substances
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4752576A (en) 1984-06-14 1988-06-21 Chiron Corporation Expression of α-1 antitrypsin in yeast
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4735217A (en) 1986-08-21 1988-04-05 The Procter & Gamble Company Dosing device to provide vaporized medicament to the lungs as a fine aerosol
US4765348A (en) 1986-12-12 1988-08-23 Brown & Williamson Tobacco Corporation Non-combustible simulated cigarette device
US5093316A (en) 1986-12-24 1992-03-03 John Lezdey Treatment of inflammation
US5217951A (en) 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
US5166134A (en) 1986-12-24 1992-11-24 John Lezdey Treatment of allergic rhinitis
US5290762A (en) 1986-12-24 1994-03-01 John Lezdey Treatment of inflammation
US5008242A (en) 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US5159940A (en) 1988-07-22 1992-11-03 Philip Morris Incorporated Smoking article
US4892109A (en) 1989-03-08 1990-01-09 Brown & Williamson Tobacco Corporation Simulated smoking article
US6068994A (en) 1989-08-07 2000-05-30 Chiron Corporation Ubiquitin expression system
US5113855A (en) 1990-02-14 1992-05-19 Newhouse Michael T Powder inhaler
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US5114953A (en) 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5268384A (en) 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5256657A (en) 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
US5287850A (en) 1991-08-20 1994-02-22 Habley Medical Technology Corporation Timing and velocity controlled powered pharmaceutical inhaler
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
FR2696080B1 (fr) 1992-09-30 1994-12-23 Jesus Covarrubias Filtre à cigarette pour l'administration de taurine par inhalation.
US5441060A (en) 1993-02-08 1995-08-15 Duke University Dry powder delivery system
AU671724B2 (en) 1993-03-16 1996-09-05 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as metalloproteinase inhibitors
CA2160139A1 (en) 1993-04-07 1994-10-13 Richard Edward Galardy Synthetic matrix metalloprotease inhibitors and uses thereof
US5594106A (en) 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US6037472A (en) 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
DE19541873A1 (de) 1995-11-09 1997-05-15 Rhodia Ag Rhone Poulenc Filterzigarette
WO1997042168A1 (en) 1996-05-06 1997-11-13 Zeneca Limited Thio derivatives of hydroxamic acids
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5780440A (en) 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
GB9715962D0 (en) 1996-08-23 1997-10-01 Zeneca Ltd Sulfonamides
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
EP0929517B1 (en) 1996-10-02 2002-06-12 Novartis AG Hydroxamic acid derivatives
AU6843498A (en) 1997-03-28 1998-10-22 Zeneca Limited Process for the preparation of n-(3-hydroxy-succinyl)-amino acid derivatives
FR2762315B1 (fr) 1997-04-22 1999-05-28 Logeais Labor Jacques Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
US6124257A (en) 1997-08-28 2000-09-26 Lezdey; John Method of treatment
US20010006939A1 (en) 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US5972986A (en) 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
EP1047450B1 (en) 1997-12-23 2002-10-02 Warner-Lambert Company Ace inhibitor-mmp inhibitor combinations
GB9804504D0 (en) 1998-03-03 1998-04-29 Leo Pharm Prod Ltd Matrix metalloproteinase inhibitors
US5996589A (en) 1998-03-03 1999-12-07 Brown & Williamson Tobacco Corporation Aerosol-delivery smoking article
CZ20012060A3 (cs) 1998-12-09 2001-11-14 American Home Products Corporation Thiomočovinové sloučeniny obsahující acetamid a substituovaný acetamid jako inhibitory herpes virů
AU3511500A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
CA2387351C (en) 1999-10-19 2009-09-08 Merck & Co., Inc. Indole derivatives as tyrosine kinase inhibitors
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
CZ20022413A3 (cs) 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6637430B1 (en) 2000-06-16 2003-10-28 Ponwell Enterprises Limited Respiratory delivery system with power/medicament recharge assembly
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
EP1366175B1 (en) 2000-12-18 2008-01-23 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
WO2002053138A2 (en) 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
PA8539301A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
US6544497B2 (en) 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6789546B2 (en) 2001-06-26 2004-09-14 Technion Research & Development Foundation Ltd. Filters for preventing or reducing tobacco smoke-associated injury in the aerodigestive tract of a subject
US20030211548A1 (en) 2002-01-29 2003-11-13 Oncolmmunin, Inc. Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
WO2003068188A1 (en) 2002-02-18 2003-08-21 University Of Southampton Combination therapy for respiratory disorders
AU2003214108A1 (en) 2002-03-08 2003-09-22 Novartis Ag Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
US7165362B2 (en) * 2002-07-15 2007-01-23 Apple Computer, Inc. Glass support member
US6810883B2 (en) 2002-11-08 2004-11-02 Philip Morris Usa Inc. Electrically heated cigarette smoking system with internal manifolding for puff detection
CA2526222A1 (en) 2003-05-16 2004-12-02 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease associated with matrix metalloprotease inhibitors
US20060205671A1 (en) 2003-07-02 2006-09-14 Jakob Vinten-Johansen Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury
ATE530165T1 (de) * 2003-11-14 2011-11-15 Baxter Int Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
EP1737499A4 (en) * 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1045799A (ja) * 1982-08-13 1998-02-17 Zymogenetics Inc 形質転換酵母を用いて製造した蛋白質
JP2003523393A (ja) * 2000-02-25 2003-08-05 アラキス リミテッド 呼吸器疾患治療用メタロプロティナーゼ阻害剤
WO2003035610A1 (en) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Sulfonamide derivative having mmp inhibitory activity
WO2003091242A1 (en) * 2002-04-26 2003-11-06 Takeda Pharmaceutical Company Limited Novel thiol derivative, process for producing the same and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528234A (ja) * 2013-08-05 2016-09-15 フォールマン、ジェラルド 喫煙の悪影響を減らす新規手段

Also Published As

Publication number Publication date
EP1737499A4 (en) 2009-07-22
WO2005086915A2 (en) 2005-09-22
US7914771B2 (en) 2011-03-29
EP1737499A2 (en) 2007-01-03
CA2559062A1 (en) 2005-09-22
WO2005086915A3 (en) 2006-03-23
AU2005221151A1 (en) 2005-09-22
US20050201951A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
JP2007528409A (ja) プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置
JP2656944B2 (ja) タンパク質性治療剤のエアロゾール化
ES2664624T3 (es) Alfa-I antitripsina para tratar episodios de exacerbación de enfermedades pulmonares
JP2001518518A (ja) 分泌性白血球プロテアーゼインヒビターの乾燥粉末薬学的組成物
AU691514B2 (en) Stabilization of aerosolized proteins
ES2887358T3 (es) Inhibidor de Alfa1-Proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares
US20100124536A1 (en) Hemophilia Treatment by Inhalation of Coagulation Factors
US20040175383A1 (en) Methods and compositions for treatment of otitis media
EP1684719B1 (en) Alpha 1-antitrypsin compositions and treatment methods using such compositions
JP2006510657A5 (https=)
Vogelmeier et al. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers.
JP2007524607A6 (ja) 凝固因子の吸入による血友病処置
Chen et al. Targeting Neutrophil Serine Proteinases in Alpha 1 Antitrypsin Deficiency
CN115811969A (zh) 用于预防和治疗纤维化和炎性病症的组合物和方法
WO2025210089A1 (en) A combination of vasoactive intestinal peptide (vip) receptor agonist and a mucolytic agent against inflammatory diseases of the respiratory tract
WO2005049801A2 (en) Dry protein formulation
Stockleyb et al. Neutrophil elastase inhibitors
MXPA00003231A (en) Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110506

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110511

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110513

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110518

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120120